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Highlights 
 Varicella zoster virus reactivation causes serum antibody boosting. 
 Antibody titres at 1, 3 and 6 months following zoster diagnosis reflect baseline varicella 
zoster virus load. 
 Antibody titres could discriminate patients post shingles from healthy blood donors, 1 to 6 
months after shingles. However, to achieve a sensitivity of 80%, the specificity is between 55 
and 70%, whilst to achieve 80% specificity, the sensitivity is between 35 and 70%. 
 
ABSTRACT  
Background: Acute varicella zoster virus (VZV) replication in shingles is accompanied by VZV antibody 
boosting. It is unclear whether persisting virus shedding affects antibody levels. 
Objectives: To investigate the relationship between VZV viral load and antibody titres in shingles 
patients during six months following diagnosis and assess whether VZV antibody titre could 
discriminate patients with recent shingles from healthy population controls. 
Study design: A prospective study of 63 patients with active zoster.  Blood samples were collected at 
baseline, one, three and six months to measure VZV DNA and IgG antibody titre. We compared VZV 
antibody titres of zoster patients and 441 controls.  
Results: In acute zoster, viral load was highest at baseline and declined gradually over the following 
six months. Mean antibody titres rose fourfold, peaking at one month and remaining above baseline 
levels throughout the study. Antibody levels at one, three and six months after zoster were 
moderately correlated with baseline but not subsequent viral load.  Regarding use of antibody titres 
to identify recent shingles, to achieve 80% sensitivity, specificity would be 23.4%, 67.7%, 64.8% and 
52.6%, at baseline, visit 2, 3 and 4 respectively, whilst to achieve 80% specificity, sensitivity would be 
28.3%, 66.1%, 52.6%, 38.6%, at baseline, visit 2, 3 and 4 respectively.    
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Conclusions: Clinical VZV reactivation boosted VZV antibody levels and the level of boosting was 
dependent upon baseline viral replication. While antibody titres could discriminate patients with 
shingles 1-6 months earlier from blood donor controls, there was a large trade-off between 
sensitivity and specificity. 
 
Key words: Antibody; Varicella zoster virus; Herpes zoster; Viral load
1. Background 
Primary infection with varicella zoster virus (VZV) causes chickenpox, following which the virus 
establishes latency. It reactivates in up to 25% of individuals to cause the painful dermatomal rash 
known as shingles (herpes zoster).  During chickenpox or shingles, viral DNA is detectable in skin 
lesions, blood and saliva1,2.  Viral replication is accompanied by boosting of VZV antibodies 
consistent with antigenic, or endogenous, boosting.  Few data exist, however, confirming the 
relationship between viral load and antibody titres during, and following, acute clinical VZV disease. 
 
The extent to which the presence of persisting viral DNA in blood or saliva indicates active viral 
replication likely to induce an immune response is also unclear.  Immunocompetent children with 
chickenpox clear viral DNA rapidly so that it is no longer detectable two weeks after the rash has 
healed3.  In contrast, VZV DNA has been detected in blood for up to 6 months following shingles, 
albeit with falling loads4.  Asymptomatic shedding of VZV in saliva occurs more frequently in 
individuals who are immune disadvantaged5-7. Better understanding of the spectrum of VZV 
reactivation is needed to inform use of biological markers of VZV reactivation in research.   
 
2. Objectives 
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We aimed to investigate the relationship between VZV DNA levels and antibody titres by following 
acute shingles patients over 6 months, and to assess whether VZV antibody titre could discriminate 
patients with recent shingles from population controls for future research. 
 
3. Study design 
3.1 Study participants 
Patients with shingles presenting to GPs in London between 2001 and 2003 were recruited 
consecutively for a prospective cohort study of disease burden, clinical and laboratory indices of 
zoster (described elsewhere)4. Diagnosis was confirmed through detection of VZV DNA from vesicle 
fluid by PCR in patients with clinically-suspected zoster.  Patients completed a baseline survey that 
included demographic information, history of chickenpox and previous shingles episodes, immune 
status (including underlying illnesses and current treatment) and detailed information about the 
shingles episode (timing, symptoms, medications).  Blood samples were taken at baseline, one, three 
and six months to measure IgG antibody titre and viral load.  Blood samples from healthy blood 
donors from a single time-point were also collected. 
3.2 Viral load and antibody measurements 
Viral load was determined through detection and quantification of VZV DNA from whole blood. DNA 
extraction was performed using a QIAamp DNA blood mini kit (Qiagen Ltd, United Kingdom), with 
eluted DNA stored at -20oC.  VZV DNA was quantified using a real-time PCR assay, which had a 
sensitivity threshold of <10 VZV copies/µl(10).  VZV IgG antibody titres were measured using a 
validated in-house time resolved fluorescence immunoassay8. Serum dilutions were tested in 
duplicate and the Europium counts obtained were interpolated against a standard curve of British 
Standard VZV antibody (NIBSC 90/690) covering the VZV IgG range 0.39-50mIU/ml. Sera producing 
Europium counts outwith the curve were retested at appropriate dilutions. Duplicate results were 
averaged and multiplied by the dilution factor to obtain a final mean antibody level.  
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3.3 Statistical methods 
We recoded implausible IgG values above the 95th blood donor percentile as missing (n=23) and log 
transformed viral load and antibody titre to provide a normal distribution. We summarised the 
median, IQR and mean of the log transformed viral load and antibody titre at each time point. As 
there was no evidence of a non-linear association between logged mean viral DNA load and logged 
mean antibody titre we used Pearson’s correlation coefficients to investigate associations between 
these variables at the same and subsequent time points for shingles patients. These relationships 
were further explored using multivariable linear regression models. Potential confounding effects of 
age, sex, ethnicity, immunosuppression, days since rash onset, prodromal symptoms, disseminated 
rash and antiviral treatment were investigated using causal diagrams. Variables were retained if they 
were theoretically relevant confounders, and/or associated with both outcome and exposure at the 
10% significance level using a forward selection approach.  
To determine whether recent zoster could be identified from antibody levels, we undertook ROC 
analysis, comparing antibody levels in healthy controls with zoster patients. Antibody cut-off values 
(not on the log scale) to achieve 80% and 90% sensitivity or specificity, were calculated for each visit 
separately (along with the corresponding sensitivity or specificity), after adjusting for age and sex.   
 
4. Results 
The study comprised 63 patients with shingles, with a median age of 56 years (IQR 37-71 years) of 
whom 34 (54.0%) were male, and 441 blood donor controls (table 1). 
 
Viral load among shingles patients was highest at baseline and lowest at six months. Antibody titres 
rose from baseline to be maximal at one month then gradually declined, although titres remained 
elevated above baseline levels at six months (figure 1).  
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Viral load at baseline was positively associated with antibody titres at one, three and six months as 
shown in figure 2, although the strength of the associations were small to moderate.  There was 
some evidence (P=0.033) of a small negative correlation (r=-0.285) between viral load at one month 
and antibody titre at six months, but there were otherwise no significant associations between viral 
load measurements taken after baseline and later antibody titres. In multivariable linear regression 
models adjusted for age, sex, ethnicity and immune status, higher baseline viral load was associated 
with a higher antibody titre at one, three and six months (figure 2).  
 
Antibody titre was higher in shingles patients at 1, 3 and 6 months from baseline, compared to 
controls; median log antibody titre was 3.16 (IQR: 2.92-3.45) among controls. ROC analysis (figure 3) 
demonstrated that to achieve 80% sensitivity, specificity would be 23.4%, 67.7%, 64.8% and 52.6%, 
whilst to achieve 80% specificity, sensitivity would be 28.3%, 66.1%, 52.6% and 38.6% at baseline, 
visit 2, 3 and 4 respectively.  The best obtainable specificity, at 90% sensitivity, was 59%, and the 
best obtainable sensitivity, at 90% specificity, was 39% (data not shown). 
5. Discussion 
We showed that baseline, rather than subsequent viral load was the strongest predictor of antibody 
titre at one, three and six months after an acute shingles episode.  Antibody titres remained 
persistently elevated in shingles patients compared to healthy blood donors for at least six months, 
with the greatest discrimination between groups occurring at one month post shingles. Antibody 
titres could discriminate patients with recent shingles from healthy controls, however there was a 
significant trade-off between sensitivity and specificity. 
 
Reactivation of latent VZV is largely kept in check through cell-mediated immunity9, with antibodies 
playing very little role in VZV control.  Individuals with severe clinical VZV reactivation including 
those who develop post-herpetic neuralgia often have high antibody titres, which are believed to 
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correlate with more widespread VZV replication10. Our findings are consistent with this hypothesis.  
The lack of association found between viral loads at one, three and six months and antibody titres at 
the same and subsequent time points suggests that persistence of serum VZV DNA after shingles 
may be a function of decay rather than ongoing replication, although this finding needs to be tested 
in other larger populations.   
 
Antibody titre cut-off values could be used to identify patients with shingles 1-6 months previously, 
but with a large trade-off between sensitivity and specificity. Whether researchers choose to set cut 
off values to achieve a high sensitivity e.g. when using antibody titre as an initial screening test for 
recent shingles, or to be highly specific e.g. in a test aimed at diagnostic confirmation, will depend on 
the nature and context of their research.  
 
This study was limited by relatively small numbers of patients. Data on other potential confounding 
factors such as ethnicity and immune status in blood donors was lacking, so only age and sex were 
accounted for in the shingles patient-blood donor analysis.  Nevertheless, as these factors were not 
associated with antibody titre in shingles patients, results are unlikely to have been notably affected. 
 
In conclusion, there is evidence for endogenous boosting of VZV antibody levels by clinical VZV 
reactivation and the level of boosting is dependent upon baseline viral replication. Additionally, 
antibody titres could discriminate post-shingles patients from healthy controls, although whether to 
prioritise specificity or sensitivity would depend on the study question.   
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Figure 1. Log VZV viral load and antibody titres over time.
Log viral load Log antibody titre
n=63 
n=60 
n=59 
n=59 
n=58 
n=57 
n=58 
n=57 
AC
CE
PT
ED
 M
AN
US
CR
IPT
11 
 
r= .108 (P=0.413)
Adj. coef=0.04
(95%CI:-0.18 to 0.26)
2
3
4
5
0
2
0
4
0
6
0
8
0
0 20 40 60 80
0
2
0
4
0
6
0
8
0
0 20 40 60 80
0
2
0
4
0
6
0
8
0
0 20 40 60 80
r= .406 (P=0.001)
Adj. coef=0.29
(95%CI:0.12 to 0.45)
2
3
4
5
r=-.176(P=0.182)
Adj. coef=-0.08
(95%CI:-0.21 to 0.04)
0
2
0
4
0
6
0
8
0
0 20 40 60 80
0
2
0
4
0
6
0
8
0
0 20 40 60 80
r= .425 (P=0.001)
Adj. coef=0.29
(95%CI:0.14 to 0.44)
2
3
4
5
r=-.195(P=0.147)
Adj. coef=-0.06
(95%CI:-0.18 to 0.05)
r= .095 (P=0.484)
Adj. coef=0.03
(95%CI:-0.07 to 0.14)
0
2
0
4
0
6
0
8
0
0 20 40 60 80
r= .262 (P=0.049)
Adj. coef=0.19
(95%CI:0.04 to 0.34)
2
3
4
5
0 1 2 3 4 5
r=-.285 (P=0.033)
Adj. coef=-0.07
(95%CI:-0.19 to 0.05)
0 1 2 3 4 5
r=-.076 (P=0.581)
Adj. coef=-0.05
(95%CI:-0.16 to 0.07)
0 1 2 3 4 5
r=-.153 (P=0.255)
Adj. coeff=-0.06
(95%CI:-0.16 to 0.05)
0 1 2 3 4 5
Figure 2: Association between log viral load and antibody titre, at the same and various time points: Pearson correlation coefficients and 
coefficients from multivariable linear regression models displayed 
Note: Adjusted coefficients represent the effect of a one unit change in the variable value on the log mean antibody titre, adjusted for age, sex, 
ethnicity and immunosuppression status. 
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Figure 3 (with table): ROC curve with table showing antibody cut-off values and 
specificity/sensitivity if test was required to have 80% sensitivity/specificity, at each visit. 
 
 
 
 
*If the VZV IgG antibody titre value is greater than or equal to the cut-off, then the individual is declared positive (affected) 
by this cut-off approach, else negative (healthy), and these are compared to the actual status to determine sensitivity and 
specificity. 
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80% 
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Table 1 Baseline characteristics of shingles patients and blood donors 
Variable Group, frequency (%) 
Shingles patients (N=63) Blood donors (N=441) 
Age, median (IQR), yrs 56 (37-71) 42 (29-51) 
Sex 
Male 
Female 
 
34 (54.0) 
29 (46.0) 
 
207 (46.9) 
234 (53.1) 
Ethnicity* 
Afro-Caribbean 
Asian 
Caucasian 
Turkish-Caucasian 
Other 
 
4 (6.3) 
3 (4.8) 
42 (66.7) 
9 (14.3) 
5 (7.9) 
 
Data not available 
Immunocompromised 
Yes 
No 
 
7 (11.1) 
56 (88.9) 
 
Data not available 
Rash age, days 
0-2 
3-4 
5-6 
6+ 
 
7 (11.1) 
21 (33.3) 
22 (34.9) 
13 (20.6) 
 
N/A 
Prodromal symptoms 
Yes 
No 
 
46 (73.0) 
17 (27.0) 
 
N/A 
Disseminated rash 
Yes 
No 
Missing 
 
7 (11.7) 
53 (88.3) 
3 (-) 
 
N/A 
 
Antiviral medication for 
shingles 
Yes 
No 
 
43 (68.3) 
20 (31.7) 
 
N/A 
*modelled as ‘Caucasian’ versus ‘Non Caucasian’ 
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